Viking Therapeutics Inc VKTX
Optionality holds this up; Moat is the soft spot.
| Moat | 2.0 |
| Management | 5.0 |
| Valuation | 5.0 |
| Risk · 10 = lowest | 3.0 |
| Business model | 5.0 |
| Optionality | 6.0 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no card